BMC Cancer (Dec 2022)

Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial

  • Natsuo Tomita,
  • Hiromichi Ishiyama,
  • Chiyoko Makita,
  • Yukihiko Ohshima,
  • Aiko Nagai,
  • Fumiya Baba,
  • Mayu Kuno,
  • Shinya Otsuka,
  • Takuhito Kondo,
  • Chikao Sugie,
  • Tatsuya Kawai,
  • Taiki Takaoka,
  • Dai Okazaki,
  • Akira Torii,
  • Masanari Niwa,
  • Nozomi Kita,
  • Seiya Takano,
  • Shogo Kawakami,
  • Masayuki Matsuo,
  • Tomoyasu Kumano,
  • Makoto Ito,
  • Sou Adachi,
  • Souichiro Abe,
  • Takayuki Murao,
  • Akio Hiwatashi

DOI
https://doi.org/10.1186/s12885-022-10371-3
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Radiobiological daily changes within tumors are considered to be quite different between stereotactic radiotherapy (SRT) (e.g., 50 Gy in 4 fractions) and conventional radiotherapy (e.g., 60 Gy in 30 fractions). We aim to assess the optimal interval of irradiation in SRT and compare outcomes of daily irradiation with irradiation at two- to three-day intervals in SRT for patients with one to five brain metastases (BM). Methods This study is conducted as a multicenter open-label randomized phase II trial. Patients aged 20 or older with one to five BM, less than 3.0 cm diameter, and Karnofsky Performance Status ≥70 are eligible. A total of 70 eligible patients will be enrolled. After stratifying by the number of BMs (1, 2 vs. 3–5) and diameter of the largest tumor (< 2 cm vs. ≥ 2 cm), we randomly assigned patients (1:1) to receive daily irradiation (Arm 1), or irradiation at two- to three-day intervals (Arm 2). Both arms are performed with total dose of 27-30 Gy in 3 fractions. The primary endpoint is an intracranial local control rate, defined as intracranial local control at initially treated sites. We use a randomized phase II screening design with a two-sided α of 0∙20. The phase II trial is positive with p < 0.20. All analyses are intention to treat. This study is registered with the UMIN-clinical trials registry, number UMIN000048728. Discussion This study will provide an assessment of the impact of SRT interval on local control, survival, and toxicity for patients with 1–5 BM. The trial is ongoing and is recruiting now. Trial registration UMIN000048728. Date of registration: August 23, 2022. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000055515 .

Keywords